Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Intangibles (2016 - 2024)

ImmunityBio (IBRX) has disclosed Intangibles for 11 consecutive years, with $16.1 million as the latest value for Q2 2024.

  • Quarterly Intangibles fell 15.45% to $16.1 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Jun 2024, down 15.45% year-over-year, with the annual reading at $17.1 million for FY2023, 14.55% down from the prior year.
  • Intangibles for Q2 2024 was $16.1 million at ImmunityBio, down from $16.6 million in the prior quarter.
  • The five-year high for Intangibles was $22.3 million in Q1 2022, with the low at $1.4 million in Q4 2021.
  • Average Intangibles over 5 years is $13.2 million, with a median of $17.1 million recorded in 2023.
  • The sharpest move saw Intangibles surged 1454.17% in 2022, then dropped 15.45% in 2024.
  • Over 5 years, Intangibles stood at $1.5 million in 2020, then dropped by 2.94% to $1.4 million in 2021, then soared by 1308.66% to $20.0 million in 2022, then fell by 14.55% to $17.1 million in 2023, then decreased by 6.06% to $16.1 million in 2024.
  • According to Business Quant data, Intangibles over the past three periods came in at $16.1 million, $16.6 million, and $17.1 million for Q2 2024, Q1 2024, and Q4 2023 respectively.